Long-Term Mortality and Morbidity Related to Congestive Heart Failure with Reduced Ejection Fraction (CHFrEF) in Palestinian Patients Maintained on Submaximal Sacubitril/Valsartan Doses: A Pilot Study

Long-Term Mortality and Morbidity Related to Congestive Heart Failure with Reduced Ejection Fraction (CHFrEF) in Palestinian Patients Maintained on Submaximal Sacubitril/Valsartan Doses: A Pilot Study

Background . The efficacy of sacubitril/valsartan, a newly introduced combination drug for heart failure with reduced ejection fraction (HFrEF), was demonstrated in the PARADIGM-HF trial conducted in Western countries. However, these findings need to be verified in the Middle Eastern context, where...

Full description

Bibliographic Details
Main Authors: Raed Aqel, Tareq Z. Alzughayyar, Sadi A. Abukhalaf, Rami A. Misk, Jihad Samer Zalloum
Format: Article
Language:English
Published: SAGE Publications 2021-12-01
Series:Journal of the Renin-Angiotensin-Aldosterone System
Online Access:https://doi.org/10.1155/2021/1829873

Internet

https://doi.org/10.1155/2021/1829873

Similar Items